The gene for Huntington’s disease “was cloned in 1993, and everyone thought there was going to be a treatment right around the corner,” Sarah Tabrizi told the audience at the 2023 Annual Meeting of the Society for Neuroscience. Then, “it took 25 years for the first trial targeting the Huntington gene.”
Protein tyrosine kinase 7 (PTK7) is a pseudo tyrosine kinase overexpressed in many cancer types such as ovarian, triple-negative breast cancer (TNBC), non-small-cell lung cancer, small-cell lung cancer and bladder cancer, but limited expression in normal tissues.
Researchers from the University of Michigan and affiliated organizations presented data from a study that identified a link between a new neurodevelopmental disorder and biallelic variants in the EPB41L3 gene, which encodes band 4.1-like protein 3 that plays important roles in neuronal development, myelination and cytoskeletal organization.
Researchers from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Doma Biopharmaceutical (Suzhou) Co. Ltd. reported the discovery and preclinical data of DM-005, a novel fully human EGFR × MET bispecific antibody-drug conjugate (ADC) being developed for the treatment of cancer.
KLRG1 is expressed on a subset of T and NK cells, with KLRG1+CD8+ T cells having demonstrated strong antitumor cytotoxicity by releasing IFN-γ and TNF-α.
Researchers from Chugai Pharmaceutical Co. Ltd. presented preclinical data of SAIL-66, a trispecific antibody targeting Claudin-6 (CLDN6), CD137 (4-1BB) and CD3, for cancer immunotherapy.
Researchers from Arcturus Therapeutics Inc. and affiliated organizations presented preclinical data for LUNAR-CFTR, a novel mutation-agnostic, aerosolized CFTR replacement therapy for the treatment of cystic fibrosis (CF).
Researchers from Umoja Biopharma Inc. presented the discovery and preclinical evaluation of UB-VV200, a third-generation lentiviral vector containing a multi-domain fusion (MDF) protein consisting of a T cell-targeting anti-CD3 scFv and costimulatory proteins.
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor involved in tumor initiation, progression, and metastasis whose endogenous ligands are highly expressed in the tumor microenvironment of aggressive tumors.
New and updated preclinical data presented at the Society for Immunotherapy of Cancer congress in San Diego, by: Abcellera, Affimed, Alligator, Allogene, Ankyra, Calidi, Candel, CDR-Live, Hotspot, Scopus.
RSS
